Live-attenuated varicella vaccine

Infectious Disease Clinics of North America

Volumn 15, Issue 1, 2001, Pages 65-81

  Gershon, Anne A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE;

ASTHMA; CELLULAR IMMUNITY; CHICKENPOX; DRUG SAFETY; IMMUNE RESPONSE; PROPHYLAXIS; REVIEW; VACCINATION; VIRUS TRANSMISSION;

EID: 0035061541     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70268-3     Document Type: Article

References (91)

1. Combination measles, mumps, rubella, and varicella vaccine
2. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy
3. Varicella vaccine studies in healthy children and adults
4. Live attenuated varicella vaccine
5. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine
6. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward
7. Experience and reason: Twenty year follow up of protective immunity of the Oka live varicella vaccine
8. Edmonston-Zagreb measles vaccine: A good vaccine with an image problem
9. Varicella and zoster in children after kidney transplantation: Long term results of vaccination
10. Administration of live varicella vaccine to children with leukemia
11. Risk of herpes zoster in children with leukemia: Varicella vaccine compared with history of chickenpox
12. Varicella vaccine of health care workers
13. Prevention of varicella
14. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
15. Varicella-related deaths among children, United States, 1997
16. Varicella-related deaths...Florida
17. Varicella-related deaths among adults - United States, 1997
18. Varicella: Report of two fatal cases with necropsy, virus isolation, and serologic studies
19. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents
20. Live attenuated varicella vaccine
21. Report of the Committee on Infectious Diseases
22. Consequences of varicella and herpes zoster in pregnancy: Prospective study of 1739 cases
23. Varicella in children with cancer: 77 cases
24. Varicella in children with cancer: Impact of antiviral therapy and prophylaxis
25. Chickenpox, measles, and mumps
26. Live attenuated varicella-zoster vaccine
27. Varicella-zoster virus: Prospects for control
28. Detection of antibodies to varicella-zoster virus by latex agglutination
29. Live attenuated varicella vaccine: Current status and future uses
30. Varicella vaccine: Use in immunocompromised patients
31. Live attenuated varicella vaccine: Efficacy for children with leukemia in remission. NIAID Collaborative Varicella Vaccine Study Group
32. Live attenuated varicella vaccine: Use in immunocompromised children and adults. NIAID Collaborative Varicella Vaccine Study Group
33. Detection of antibodies to varicella-zoster virus by latex agglutination
34. Immunization of healthy adults with live attenuated varicella vaccine. NIAID Collaborative Varicella Vaccine Study Group
35. Live attenuated varicella vaccine: Protection in healthy adults in comparison to leukemic children. NIAID Collaborative Varicella Vaccine Study Group
36. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. NIAID Collaborative Varicella Vaccine Study Group
37. Live attenuated varicella vaccine
38. Herpes zoster with postherpetic neuralgia - Persisting pain and frustration
39. Herpes zoster in an adult recipient of live attenuated varicella vaccine
40. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia
41. Use of live varicella vaccine in children with acute leukemia or other malignancies
42. Biologic and biophysical markers of a live varicella vaccine strain (Oka): Identification of clinical isolates from vaccine recipients
43. Analysis of varicella zoster virus (VZV) DNAs of clinical isolates by endonuclease HpaI
44. Transmission of varicella-zoster virus from a vaccinee with underlying leukemia, demonstrated by polymerase chain reaction
45. Application of a live varicella vaccine in children with acute leukemia or other malignant diseases
46. A long-term prospective study of varicella vaccine in healthy children
47. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine
48. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adults
49. Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies
50. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts
51. The risk of zoster after varicella vaccination in children with leukemia. NIAID Varicella Vaccine Collaborative Study Group
52. Administration of varicella vaccine to HIV-infected children
53. Immune response of elderly individuals to a live attenuated varicella vaccine
54. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine
55. Herpes zoster after varicella immunization
56. Reactivated and latent varicella-zoster virus in human dorsal root ganglia
57. Duration of live measles vaccine-induced immunity
58. Comparison of cell-mediated immunity (CMI) to varicella-zoster virus (VZV) in children and adults immunized with live attenuated varicella vaccine
59. Varicella: Complications and costs
60. Varicella: Clinical manifestations, epidemiology, and health impact on children
61. Antibody assays suitable for assessing immune responses to live varicella vaccine
62. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine
63. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and Pedvax-HIB® vaccines in healthy children twelve to eighteen months old. MMRV Study Group
64. Modification of chickenpox in family contacts by administration of gamma globulin
65. Postexposure varicella vaccination in siblings of children with active varicella
66. Transmission of varicella-vaccine virus from a healthy 12 month old child to his pregnant mother
67. Clinical overview of varicella vaccine: Development and early studies
68. Live attenuated varicella vaccine
69. Varicella vaccines
70. Live vaccine used to prevent the spread of varicella in children in hospital
71. Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus
72. Efficacy of high titer live attenuated varicella vaccine in healthy young children
73. Protective efficacy of varicella vaccine in clinical practice
74. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine
75. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine
76. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine
77. Live Oka/Merck varicella vaccine in healthy children: Further clinical and laboratory assessment
78. Live attenuated varicella virus vaccine: Efficacy trial in healthy children
79. Varicella: Historical perspective and clinical overview
80. Letter to editor
81. Clinical trials of varicella vaccine in healthy children
82. Varicella-zoster virus vaccine
83. Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989
84. Measles, mumps, rubella, and varicella combination vaccine: Safety and immunogenicity alone and in combination with other vaccines given to children
85. Herpes zoster following varicella vaccine in a child with acute lymphocytic leukemia
86. Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence
87. Seroconversion rates in health care workers using a latex agglutination assay after varicella virus vaccination